Sam J. Lubner, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Lubner graduated from Princeton University, Princeton, NJ, with a BA in History in 1999, and the University of Wisconsin School of Medicine, Madison, WI with a MD, in 2003. His postgraduate internship and residency training in Internal Medicine was performed at Washington University School of Medicine, Barnes-Jewish Hospital, Saint Louis, MO from 2003 to 2006, and a fellowship in Hematology/Oncology at University of Wisconsin Hospital and Clinics, Madison, WI.
UW Health Clinics
Regional Specialty Clinics
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
University of Wisconsin Hospital and Clinics, Madison, WI
Barnes-Jewish Hospital, St. Louis, MO
Barnes-Jewish Hospital, St. Louis, MO
University of Wisconsin School of Medicine and Public Health, Madison, WI, 2003
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Halverson JL Martinez-Donate AP Palta M Leal T Lubner S Walsh MC Schaaf Strickland J Smith PD Trentham-Dietz A .
Health Literacy and Health-Related Quality of Life Among a Population-Based Sample of Cancer Patients. J Health Commun. 2015 Nov;20(11):1320-9
[PubMed ID: 26161549]
Lubner MG Stabo N Lubner SJ Del Rio AM Song C Halberg RB Pickhardt PJ .
CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes. Abdom Imaging. 2015 Oct;40(7):2331-7
[PubMed ID: 25968046]
Tran NH Cavalcante LL Lubner SJ Mulkerin DL LoConte NK Clipson L Matkowskyj KA Deming DA .
Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol. 2015 Sep;7(5):252-62
[PubMed ID: 26327923]
Makielski RJ Lubner SJ Mulkerin DL Traynor AM Groteluschen D Eickhoff J LoConte NK .
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. Cancer Chemother Pharmacol. 2015 Aug;76(2):317-23
[PubMed ID: 26068189]
LoConte NK Razak AR Ivy P Tevaarwerk A Leverence R Kolesar J Siu L Lubner SJ Mulkerin DL Schelman WR Deming DA Holen KD Carmichael L Eickhoff J Liu G .
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs. 2015 Feb;33(1):169-76
[PubMed ID: 25318436]
Deming DA Maher ME Leystra AA Grudzinski JP Clipson L Albrecht DM Washington MK Matkowskyj KA Hall LT Lubner SJ Weichert JP Halberg RB .
Phospholipid ether analogs for the detection of colorectal tumors. PLoS One. 2014;9(10):e109668
[PubMed ID: 25286226]
LoConte NK Holen KD Schelman WR Mulkerin DL Deming DA Hernan HR Traynor AM Goggins T Groteluschen D Oettel K Robinson E Lubner SJ .
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs. 2013 Aug;31(4):943-8
[PubMed ID: 23263993]
Mohammed TA Holen KD Jaskula-Sztul R Mulkerin D Lubner SJ Schelman WR Eickhoff J Chen H Loconte NK .
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist. 2011;16(6):835-43
[PubMed ID: 21632454]
Lubner SJ Kunnimalaiyaan M Holen KD Ning L Ndiaye M Loconte NK Mulkerin DL Schelman WR Chen H .
A preclinical and clinical study of lithium in low-grade neuroendocrine tumors. Oncologist. 2011;16(4):452-7
[PubMed ID: 21393344]
Lubner SJ Mahoney MR Kolesar JL Loconte NK Kim GP Pitot HC Philip PA Picus J Yong WP Horvath L Van Hazel G Erlichman CE Holen KD .
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010 Jul 20;28(21):3491-7
[PubMed ID: 20530271]
Lubner SJ Loconte NK Holen KD Schelman W Thomas JP Jumonville A Eickhoff JC Seo S Mulkerin DL .
A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2010 Jul;9(3):157-61
[PubMed ID: 20643620]